Incubator Tenant Profiles

BioCangen Inc. is a biotechnology company that focuses on developing and commercializing technologies for early cancer detection and prediction of cancer chemosensitivity. BioCangen has developed an Ultra-Sensitive Gene Methylation Amplification Technology (USGMAT) for the detection of early cancer. The USGMAT kit is currently in clinical trials. In addition, BioCangen is establishing an epigenetics-based assay specifically for measuring cancer chemosensitivity. This assay can be potentially applied to prediction of individualized chemotherapy response in several types of cancer including colon, lung, breast and ovarian cancer.

BioMolecular, Inc. is a leading technology, product and service provider for the life science community. The company has developed a variety of biological research reagents, such as ultra-speed clone vector, ultra-sensitive PCR system, one step Western blot and magic protein sample solution. These reagents are widely used in molecular biological research, drug discovery and clinical diagnosis. The company’s research services include customer gene expression, DNA and RNA purification, gDNA and cDNA library construction, PCR and gene clone, RT-PCR, clinical assay, primer and gene synthesis, DNA sequencing and contracting research project.

Biosignal Group was founded by SUNY neuroscientist Dr. Andre Fenton to commercialize neuroscience discoveries and sell them to the neuroscience research and clinical markets.  BSG has developed a patent-applied digital signal telemeter (“DT”), which captures and transmits broadband bioelectric signals wirelessly by radio to a receiver device for analysis and storage in a computer.   The DT is an innovative, miniature, battery-operated, portable unit.  The company also sells a proprietary video-based tracking system for behavioral research.  

Cytira is a drug discovery and development company with research programs aimed at the treatment, cure and prevention of neurological and endocrine disorders.  A core technology of the company is the use of approaches that increase insulin sensitivity in the brain.  These agents may have benefits for patients suffering from diabetes, obesity, polycystic ovary syndrome and certain neurological disorders.

The IAVI Vaccine Research and Development Lab is a versatile facility designed to create novel immunogens, develop viral vectors, evaluate potency and advance promising candidates to clinical evaluation.

The Lab has also established common preclinical standards for the AIDS vaccine field and supports two consortia comprised of scientists from IAVI and academic institutions. Their goals are to understand the basis of naturally evoked, broadly neutralizing antibodies against HIV and to understand the mechanism for the strong protection of live attenuated SIV vaccination in non-human primates, both to inform the design of AIDS vaccine candidates.  

Millisecond Technologies Corp. is a research and development company, specializing in advanced technology for selective inactivation of microorganisms in liquid media. MSTC relates to a pharmaceutical and medical biotechnology. The company owns the unique thermal and physical process. This exceptional scientific method may include applications such as cell to cell fusion, cell fusion with liposomes, cell mediated immune response vaccine, preservation of blood plasma and intravenous fluids. Each of these applications represents an independent opportunity and has substantial economic potential.

Phoebus Optoelectronics LLC was founded in 2003 to research and develop nanoscale optoelectronic devices that provide higher-performance, lower-cost technology solutions to manufacturers in the defense and telecommunications industries, as well as to government agencies and academic institutions. Phoebus is developing a variety of photodetectors based on newfound physics within the nanoscale regime, including Quantum Wire Infrared Photodetectors and Advanced Silicon Photodetectors.